Comparative Bioavailability of Two Cefdinir Suspension Formulations in Middle Eastern Healthy Volunteers after Single Oral Administration

Abstract

The aim of this study was to compare the bioavailability, after oral administration, of the generic “Adcef^® Suspension” (test) (125 mg/5 ml cefdinir; CAS 91832-40-5), with that of a commercially available original preparation (reference) (125 mg/5 ml cefdinir). For this purpose a randomized, two-way, crossover, bioequivalence study was performed in 24 healthy, male volunteers. The Middle Eastern selected volunteers were divided into two groups of 12 subjects. One group was treated with the reference standard and the other one with the test, with a crossover after the drug washout period of 7 days. Blood samples were collected at fixed time intervals and cefdinir concentrations were determined by a validated HPLC assay method. The pharmacokinetic parameters AUC_0–24, AUC_0–∞, C_max, T_max, K_e and T_1/2 were determined for both formulations and were compared statistically to evaluate the bioequivalence between the two brands of cefdinir, using the statistical model recommended by the FDA. The analysis of variance (ANOVA) did not show any significant difference between the two formulations and 90% confidence intervals (CI) fell within the acceptable range for bioequivalence. Based on the statistical evaluation it was concluded that the two formulations exhibit

Key words

Adcef® - Antibacterials - CAS 91832-40-5 - Cefdinir, bioequivalence, Middle Eastern volunteers

• References

• 1 Inamoto Y, Chiba T, Kamimura T, Takaya T. FK482, a new orally active cephalosporin synthesis and biological properties. J Antibiot (Tokyo). 1988; 41: 828-830
• 2 Sakane K, Inamoto Y, Takaya T. A new oral cephem, cefdinir: its structure-activity relationships and biological profile. Jpn J Antibiot. 1992; 45: 909-925
• 3 Montvale NJ, Thomson PDR. Physician’s Desk Reference. , 57th ed. [M]. Oradell (New Jersey): Medical Economics; 2003. p 489
• 4 Arguedas A, Dagan R, Leibovitz E, Hoberman A, Pichichero M, Paris M. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J. 2006; 25: 211-218
• 5 Hardley JA. The efficacy of cefdinir in acute bacterial rhinosinusitis. Expert Opin Pharmacol. 2006; 7: 1075-1083
• 6 Holas C, Chiu YL, Notario G, Kapral D. A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years. Clin Ther. 2005; 27: 1950-1960
• 7 Shimada K, Oka S. Effect of food on bioavailability of cefdinir. Chemotherapy (Tokyo). 1989; 37 (Suppl 2) 246-256
• 8 Shimada K, Shishido A, Tsunoo M. Phase 1 study of cefdinir. Chemotherapy (Tokyo). 1989; 37 (Suppl 2) 208-245
• 9 Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992
• 10 EMEA guidance. Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). London; 26 July 2001.
• 11 FDA guidance. Guidance for industry: Statistical approaches to establishing bioequivalence. Rockville, MD; 31 January 2001.